Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25404826 | 0.87 | EGFR (0.49) | EGFRALKIRAK4MAP3K7IRAK1 | |
| SCHEMBL25405702 | 0.87 | EGFR (0.49) | EGFRALKIRAK4MAP3K7IRAK1 | |
| SCHEMBL26585002 | 0.84 | EGFR (0.46) | EGFRALKIRAK4MAP3K7IRAK1 | |
| SCHEMBL25406226 | 0.76 | IRAK4 (0.45) | ALKIRAK4MAP3K7IRAK1SPR | |
| SCHEMBL25406231 | 0.76 | IRAK4 (0.45) | ALKIRAK4MAP3K7IRAK1SPR | |
| SCHEMBL25405535 | 0.76 | EGFR (0.51) | EGFRALKSPRMET | |
| SCHEMBL26584986 | 0.73 | IRAK4 (0.42) | ALKIRAK4MAP3K7IRAK1MET | |
| SCHEMBL26584987 | 0.73 | ALK (0.39) | ALKIRAK4MAP3K7IRAK1MET | |
| SCHEMBL25407952 | 0.73 | EGFR (0.48) | EGFRALKSPRMET | |
| SCHEMBL25404859 | 0.72 | ALK (0.39) | EGFRALKIRAK4MAP3K7IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885ALK 85/4885IRAK4 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.